Literature DB >> 7947263

Establishment and characterization of a novel myeloid cell line from the bone marrow of a patient with the myelodysplastic syndrome.

K Tohyama1, H Tsutani, T Ueda, T Nakamura, Y Yoshida.   

Abstract

A novel long-term cultured myeloid cell line was established from the bone marrow of a patient with myelodysplastic syndrome (MDS). This cell line, designated MDS92, proliferated in the presence of interleukin-3 or granulocyte-macrophage colony-stimulating factor and transiently in the presence of Steel factor, with a tendency for gradual maturation, and formed myeloid colonies in the semi-solid culture condition. In addition, the MDS92 cell line represented rather complicated karyotypic abnormalities including the deletion of fifth and seventh chromosomes and a point mutation at codon 12 of the N-ras oncogene. These characteristics of the MDS92 cell line are exclusively compatible with the property of preleukaemia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7947263     DOI: 10.1111/j.1365-2141.1994.tb04904.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  18 in total

1.  DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes.

Authors:  Kensuke Kayamori; Yurie Nagai; Cheng Zhong; Satoshi Kaito; Daisuke Shinoda; Shuhei Koide; Wakako Kuribayashi; Motohiko Oshima; Yaeko Nakajima-Takagi; Masayuki Yamashita; Naoya Mimura; Hans Jiro Becker; Kiyoko Izawa; Satoshi Yamazaki; Satoshi Iwano; Atsushi Miyawaki; Ryoji Ito; Kaoru Tohyama; William Lennox; Josephine Sheedy; Marla Weetall; Emiko Sakaida; Koutaro Yokote; Atsushi Iwama
Journal:  Blood Adv       Date:  2021-01-26

2.  NPM1 ablation induces HSC aging and inflammation to develop myelodysplastic syndrome exacerbated by p53 loss.

Authors:  Claudia Morganti; Kyoko Ito; Chie Yanase; Amit Verma; Julie Teruya-Feldstein; Keisuke Ito
Journal:  EMBO Rep       Date:  2022-03-01       Impact factor: 9.071

3.  An MDS xenograft model utilizing a patient-derived cell line.

Authors:  G W Rhyasen; M Wunderlich; K Tohyama; G Garcia-Manero; J C Mulloy; D T Starczynowski
Journal:  Leukemia       Date:  2013-12-11       Impact factor: 11.528

4.  SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function.

Authors:  Jie Sun; Xin He; Yinghui Zhu; Zonghui Ding; Haojie Dong; Yimei Feng; Juan Du; Hanying Wang; Xiwei Wu; Lei Zhang; Xiaochun Yu; Allen Lin; Tinisha McDonald; Dandan Zhao; Herman Wu; Wei-Kai Hua; Bin Zhang; Lifeng Feng; Kaoru Tohyama; Ravi Bhatia; Philipp Oberdoerffer; Yang Jo Chung; Peter D Aplan; Jacqueline Boultwood; Andrea Pellagatti; Samer Khaled; Marcin Kortylewski; Flavia Pichiorri; Ya-Huei Kuo; Nadia Carlesso; Guido Marcucci; Hongchuan Jin; Ling Li
Journal:  Cell Stem Cell       Date:  2018-08-23       Impact factor: 24.633

5.  Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells.

Authors:  Aditi Shastri; Gaurav Choudhary; Margarida Teixeira; Shanisha Gordon-Mitchell; Nandini Ramachandra; Lumie Bernard; Sanchari Bhattacharyya; Robert Lopez; Kith Pradhan; Orsolya Giricz; Goutham Ravipati; Li-Fan Wong; Sally Cole; Tushar D Bhagat; Jonathan Feld; Yosman Dhar; Matthias Bartenstein; Victor J Thiruthuvanathan; Amittha Wickrema; B Hilda Ye; David A Frank; Andrea Pellagatti; Jacqueline Boultwood; Tianyuan Zhou; Youngsoo Kim; A Robert MacLeod; P K Epling-Burnette; Minwei Ye; Patricia McCoon; Richard Woessner; Ulrich Steidl; Britta Will; Amit Verma
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

6.  β-Catenin Is a Candidate Therapeutic Target for Myeloid Neoplasms with del(5q).

Authors:  Liping Li; Yue Sheng; Wenshu Li; Chao Hu; Nupur Mittal; Kaoru Tohyama; Amber Seba; You-Yang Zhao; Howard Ozer; Tongyu Zhu; Zhijian Qian
Journal:  Cancer Res       Date:  2017-06-13       Impact factor: 12.701

7.  Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest.

Authors:  Tomoko Hyoda; Takayuki Tsujioka; Takako Nakahara; Shin-ichiro Suemori; Shuichiro Okamoto; Mikio Kataoka; Kaoru Tohyama
Journal:  Cancer Sci       Date:  2015-02-20       Impact factor: 6.716

8.  BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.

Authors:  J M Bogenberger; S M Kornblau; W E Pierceall; R Lena; D Chow; C-X Shi; J Mantei; G Ahmann; I M Gonzales; A Choudhary; R Valdez; J Camoriano; V Fauble; R E Tiedemann; Y H Qiu; K R Coombes; M Cardone; E Braggio; H Yin; D O Azorsa; R A Mesa; A K Stewart; R Tibes
Journal:  Leukemia       Date:  2014-01-23       Impact factor: 11.528

9.  Five-aza-2'-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells.

Authors:  Takayuki Tsujioka; Akira Yokoi; Yoshitaro Itano; Kentaro Takahashi; Mamoru Ouchida; Shuichiro Okamoto; Toshinori Kondo; Shin-ichiro Suemori; Yumi Tohyama; Kaoru Tohyama
Journal:  Sci Rep       Date:  2015-11-18       Impact factor: 4.379

10.  The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy.

Authors:  Ekapun Karoopongse; Cecilia Yeung; John Byon; Aravind Ramakrishnan; Zaneta J Holman; Peter Y Z Jiang; Qiang Yu; H Joachim Deeg; A Mario Marcondes
Journal:  PLoS One       Date:  2014-09-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.